Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 287

Similar articles for PubMed (Select 21424368)

1.

Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study.

Ray PS, Bagaria SP, Wang J, Shamonki JM, Ye X, Sim MS, Steen S, Qu Y, Cui X, Giuliano AE.

Ann Surg Oncol. 2011 Dec;18(13):3839-47. doi: 10.1245/s10434-011-1657-8. Epub 2011 Mar 18.

PMID:
21424368
2.

c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer.

Kashiwagi S, Yashiro M, Takashima T, Aomatsu N, Kawajiri H, Ogawa Y, Onoda N, Ishikawa T, Wakasa K, Hirakawa K.

Br J Surg. 2013 Mar;100(4):490-6. doi: 10.1002/bjs.9021. Epub 2013 Jan 14.

PMID:
23319435
3.

FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer.

Ray PS, Wang J, Qu Y, Sim MS, Shamonki J, Bagaria SP, Ye X, Liu B, Elashoff D, Hoon DS, Walter MA, Martens JW, Richardson AL, Giuliano AE, Cui X.

Cancer Res. 2010 May 15;70(10):3870-6. doi: 10.1158/0008-5472.CAN-09-4120. Epub 2010 Apr 20.

4.

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.

5.

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

6.

The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.

Tang D, Xu S, Zhang Q, Zhao W.

Med Oncol. 2012 Jun;29(2):526-33. doi: 10.1007/s12032-011-9948-2. Epub 2011 Apr 26.

PMID:
21519872
7.

p53 as a marker of prognosis in African-American women with breast cancer.

Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S.

Ann Surg Oncol. 2010 May;17(5):1398-405. doi: 10.1245/s10434-009-0889-3. Epub 2010 Jan 5.

PMID:
20049641
8.

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. doi: 10.1186/bcr2230. Epub 2009 Feb 24.

9.

IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.

Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A.

Hum Pathol. 2009 Nov;40(11):1528-33. doi: 10.1016/j.humpath.2009.05.005. Epub 2009 Aug 19.

PMID:
19695680
10.

[Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].

Liu H, Fan QH, Zhang ZH, Li X, Yu HP, Liu GZ, Meng FQ.

Zhonghua Bing Li Xue Za Zhi. 2009 Jan;38(1):23-8. Chinese.

PMID:
19489221
11.

Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.

De Brot M, Rocha RM, Soares FA, Gobbi H.

Pathology. 2012 Jun;44(4):303-12. doi: 10.1097/PAT.0b013e3283534bcb.

PMID:
22544210
12.

Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer.

Spizzo G, Obrist P, Ensinger C, Theurl I, Dünser M, Ramoni A, Gunsilius E, Eibl G, Mikuz G, Gastl G.

Int J Cancer. 2002 Apr 20;98(6):883-8.

PMID:
11948467
13.

Personalizing breast cancer staging by the inclusion of ER, PR, and HER2.

Bagaria SP, Ray PS, Sim MS, Ye X, Shamonki JM, Cui X, Giuliano AE.

JAMA Surg. 2014 Feb;149(2):125-9. doi: 10.1001/jamasurg.2013.3181.

PMID:
24306257
14.

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.

Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.

Hum Pathol. 2008 Feb;39(2):167-74. Epub 2007 Nov 28.

PMID:
18045647
15.

Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas.

Karihtala P, Kauppila S, Soini Y, Arja-Jukkola-Vuorinen.

BMC Cancer. 2011 Jun 21;11:262. doi: 10.1186/1471-2407-11-262.

16.

Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer.

Kim EK, Kim HA, Koh JS, Kim MS, Kim KI, Lee JI, Moon NM, Ko E, Noh WC.

Breast Cancer Res Treat. 2011 Feb;126(1):93-9. doi: 10.1007/s10549-010-1315-z. Epub 2010 Dec 24.

PMID:
21184268
17.

[Relationship between breast cancer molecular subtypes with clinicopathological characteristics and prognosis].

Lin M, Chen ZQ, Bao Y, Li Q, Du ZG, Xu ZD, Tang F.

Zhonghua Bing Li Xue Za Zhi. 2010 Jun;39(6):372-6. Chinese.

PMID:
21055152
18.

Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.

Williams DJ, Cohen C, To TV, Page AJ, Lawson D, Sussman ZM, Nassar A.

Hum Pathol. 2009 Aug;40(8):1176-81. doi: 10.1016/j.humpath.2009.01.003. Epub 2009 Apr 14.

PMID:
19368951
19.

Expression of cancer-testis antigen CT7 (MAGE-C1) in breast cancer: an immunohistochemical study with emphasis on prognostic utility.

Krüger S, Ola V, Feller AC, Fischer D, Friedrich M.

Pathol Oncol Res. 2007;13(2):91-6. Epub 2007 Jul 3.

20.

Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.

Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O.

Hum Pathol. 2012 Jan;43(1):23-30. doi: 10.1016/j.humpath.2011.04.011. Epub 2011 Jul 20.

PMID:
21777944
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk